Evidence map›Paper›PMID 26260781›Full record

ArticleEndocrine pathology2015

Mutations of TSHR and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the Thyroid.

Guo-Xia Tong, Kokila Mody, Zhuo Wang, Diane Hamele-Bena, Marina N Nikiforova, Yuri E Nikiforov

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Endocrine pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Guo-Xia TongDepartment of Pathology, Staten Island University Hospital, 475 Seaview Avenue, New York, NY, 10305, USA. tongguoxia@gmail.com.
Kokila ModyDepartment of Pathology, Staten Island University Hospital, 475 Seaview Avenue, New York, NY, 10305, USA.
Zhuo WangDepartment of Pathology, Staten Island University Hospital, 475 Seaview Avenue, New York, NY, 10305, USA.
Diane Hamele-BenaDepartment of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA.
Marina N NikiforovaDepartment of Pathology, University of Pittsburgh Medical Center, 3477 Euler Way, Pittsburgh, PA, 15213, USA.
Yuri E NikiforovDepartment of Pathology, University of Pittsburgh Medical Center, 3477 Euler Way, Pittsburgh, PA, 15213, USA.
Staten Island University Hospital · USUniversity of Pittsburgh Medical Center · USColumbia University Irving Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell follicular carcinoma is a rare type of thyroid cancer and some with aggressive biological behavior. The cytoplasmic clearing of the neoplastic cells has been attributed to the accumulation of various substances, such as glycogen, lipid, mucin, and thyroglobulin, or distension of mitochondria or endoplasmic reticulum. However, the molecular mechanisms responsible for the characteristic appearance of the cell cytoplasm and the biological behavior remain unknown. We report here a case of aggressive clear cell follicular carcinoma of the thyroid with molecular profile using targeted next generation sequencing (NGS) that presented as a metastatic tumor in a woman with a history of breast carcinoma. The NGS data revealed the coexisting of a well-characterized loss-of-function TP53 R248Q mutation and a putative gain-of-function mutation of TSHR L272V, which was suggested by the overexpression of thyroglobulin and SLC5A5 (NIS) genes in this tumor. TP53 mutations are usually related with dedifferentiation, progression, and metastasis of thyroid carcinomas. Identification of TP53 R248Q in this tumor correlated with its aggressive clinical behavior. Gain-of-function mutation of TSHR can overstimulate the thyroid follicular cells as the elevated level of TSH does and might have contributed to the development of clear cell morphology in this tumor. This report represents the first case of clear cell follicular carcinoma of the thyroid with NGS analysis and more molecular characterization is needed to elucidate the pathogenesis and provide more prognosis-relevant information for this uncommon variant of thyroid carcinomas.

Indexed as

Adenocarcinoma, Clear CellAdenocarcinoma, FollicularAged, 80 and overFemaleHumansNeoplasm InvasivenessReceptors, ThyrotropinThyroid NeoplasmsTumor Suppressor Protein p53Receptors, ThyrotropinTP53 protein, humanTumor Suppressor Protein p53Clear cell carcinoma of the thyroidNext generation sequencing (NGS)TP53TSHR

Identifiers

PMID26260781
OpenAlexW1687279494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.